[Federal Register Volume 88, Number 146 (Tuesday, August 1, 2023)]
[Notices]
[Page 50158]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-16280]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services


Statement of Organization, Functions, and Delegations of 
Authority

AGENCY: Centers for Medicare & Medicaid Services, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Medicare and Medicaid Services, Center for 
Medicare and Medicaid Innovation (CMMI), has modified its 
organizational structure.

DATES: These new organizational structures were approved by the 
Secretary of Health and Human Services and took effect on July 27, 
2023.

FOR FURTHER INFORMATION CONTACT: Joe Kane at (410) 786-0655; 7500 
Security Blvd., Baltimore, MD.

SUPPLEMENTARY INFORMATION: Part F of the Statement of Organization, 
Functions, and Delegations of Authority for the Department of Health 
and Human Services, Centers for Medicare & Medicaid Services (CMS) 
(last amended at Federal Register, Vol. 88, No. 107, pp. 36586-36587, 
dated June 5, 2023) is further amended to reflect the establishment of 
the Division of Drug Innovation within the Center for Medicare and 
Medicaid Innovation (CMMI). Part F, Section FC. 10 (Organization) is 
revised as follows:

Center for Medicare and Medicaid Innovation (CMMI), Seamless Care 
Models Group, Seamless Care Models Group, Division of Health Plan 
Innovations

    Part F, Section FC. 20 (Functions) for the new organization is as 
follows:

Centers for Medicare & Medicaid Services

Office of the Administrator

Center for Medicare and Medicaid Innovation

Seamless Care Models Group

Division of Drug Innovation

     Directs, designs and implements models to test alternative 
approaches to payment for drugs in Medicare Part B, Part D, and 
Medicaid to optimize access to high quality, affordable drugs.
     Seeks and develop opportunities to include Part B and Part 
D drugs in alternative payment models, including accountable care 
models, and addresses regulatory and operational issues that arise when 
trying to develop a model crossing different parts of the Medicare 
program.
     Builds relationships within CMS and HHS, with States and 
Medicaid agencies, and with both governmental and non-governmental 
entities to develop, implement, and operate innovative Medicare Part B, 
Part D, and Medicaid models.
     Meets with model participants and other interested 
parties, including relevant Government officials, representatives from 
the pharmaceutical industry, payers, providers, academia, and consumer 
advocates regarding their perspectives on innovative models, research, 
and ideas for new models.
     Conducts formative research studies to inform innovative 
payment models.
     Provides technical expertise to various CMS and non-
Governmental entities on innovative Medicare Part B, Part D, and 
Medicaid payment and service delivery models to optimize access to 
affordable drugs.
    Authority: 44 U.S.C. 3101.

Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2023-16280 Filed 7-31-23; 8:45 am]
BILLING CODE 4150-28-P